Immunohistochemical marker expression by PCNSL, as compared to systemic DLBCL
. | PCNSL . | Systemic DLBCL . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Antigen . | This study; n = 83 . | Hans et al8 ; n = 152 . | Chang et al9 ; n = 42 . | Colomo et al10 ; n = 128 . | Total; n = 322 . | P . | |||
| CD10 | 2/82 (2.4) | 42 (27.6) | 16/42 (38.1) | 27/128 (21.1) | 85/322 (26.4) | < .001 | |||
| BCL-6 | 45/81 (55.6) | 85 (55.9) | 21/41 (51.2) | 91/127 (71.7) | 197/320 (61.6) | NS | |||
| MUM1 | 75/81 (92.6) | 71 (46.7) | 22 (52.4) | 68/126 (54) | 161/320 (50.3) | < .001 | |||
| CD138 | 0/56 (0) | ND | 3/40 (7.5) | 2/127 (1.6) | 5/167 (3) | NS | |||
| BCL-2 | 45/81 (55.6) | 76 (50) | ND | 74/126 (58.7) | 150/278 (54) | NS | |||
. | PCNSL . | Systemic DLBCL . | . | . | . | . | |||
|---|---|---|---|---|---|---|---|---|---|
| Antigen . | This study; n = 83 . | Hans et al8 ; n = 152 . | Chang et al9 ; n = 42 . | Colomo et al10 ; n = 128 . | Total; n = 322 . | P . | |||
| CD10 | 2/82 (2.4) | 42 (27.6) | 16/42 (38.1) | 27/128 (21.1) | 85/322 (26.4) | < .001 | |||
| BCL-6 | 45/81 (55.6) | 85 (55.9) | 21/41 (51.2) | 91/127 (71.7) | 197/320 (61.6) | NS | |||
| MUM1 | 75/81 (92.6) | 71 (46.7) | 22 (52.4) | 68/126 (54) | 161/320 (50.3) | < .001 | |||
| CD138 | 0/56 (0) | ND | 3/40 (7.5) | 2/127 (1.6) | 5/167 (3) | NS | |||
| BCL-2 | 45/81 (55.6) | 76 (50) | ND | 74/126 (58.7) | 150/278 (54) | NS | |||
For each antigen, the number and percentage of positive cases are presented for our patients with PCNSL, and 3 systemic DLBCL populations taken from the literature8-10 and their cumulative results given under Total. For each antigen, the PCNSL percentage was compared to the cumulative systemic DLBCL percentage with the chi-square test. P < .05 was considered significant.
NS indicates not significant; ND, not done.